Retatrutide (LY3437943) is a single-molecule tri-agonist research peptide targeting three receptors simultaneously: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors. It is currently one of the most studied compounds in metabolic peptide research.
Research interest centers on its multi-receptor activity profile, which distinguishes it from dual-agonist compounds. Published preclinical and early clinical data have made it a subject of significant scientific interest across metabolic, cardiovascular, and hepatic research endpoints.
assets/coa/retatrutide-coa.pdf